Mesoporous silica nanoparticles with a lipid bilayer coating for cargo delivery
A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.
1. A method of treating cancer, comprising administering to a subject in need thereof an effective amount of a nanoparticle drug carrier, wherein the nanoparticle drug carrier comprises:
a) a silica nanoparticle having a surface and defining a plurality of pores;
b) a lipid bilayer coating the surface;
c) a protonating agent disposed within the plurality of pores where said protonating agent is an ammonium salt, a trimethylammonium salt, a triethylammonium salt, or an ionophore combined with a metal salt; and
d) a drug disposed within the plurality of pores, wherein said drug consists of irinotecan, and wherein the nanoparticle drug carrier has a drug loading capacity of at least about 40% w/w.
2. The method of claim 1 , wherein the nanoparticle drug carrier has less than about 15% leakage of the drug over 20 hours in a biological buffer with pH of 7.4 at 37° C.
3. The method of claim 1 , wherein a plurality of nanoparticle drug carriers has a median diameter of less than one micron.
4. The method of claim 1 , wherein the nanoparticle drug carrier comprises a remote loading agent disposed within the plurality of pores.
5. The method of claim 1 , wherein the protonating agent converts the drug into a hydrophilic derivative that is incapable of back diffusion across the lipid bilayer.
6. The method of claim 1 , wherein the protonating agent comprises at least one anionic group.
7. The method of claim 1 , wherein the protonating agent before reaction with the drug comprises an ammonium salt, a trimethylammonium salt, or a triethylammonium salt.
8. The method of claim 7 , wherein the drug is protonated by the protonating agent and trapped in the plurality of pores as a gel-like precipitate.
9. The method of claim 7 , wherein the ammonium salt is selected from the group consisting of ammonium sulfate, ammonium sucrose octasulfate, ammonium α-cyclodextrin sulfate, ammonium β-cyclodextrin sulfate, ammonium γ-cyclodextrin sulfate, ammonium phosphate, ammonium α-cyclodextrin phosphate, ammonium β-cyclodextrin phosphate, ammonium γ-cyclodextrin phosphate, ammonium citrate, and ammonium acetate.
10. The method of claim 7 , wherein the trimethylammonium salt is selected from the group consisting of trimethylammonium sulfate, trimethylammonium sucrose octasulfate, trimethylammonium α-cyclodextrin sulfate, trimethylammonium β-cyclodextrin sulfate, trimethylammonium γ-cyclodextrin sulfate, trimethylammonium phosphate, trimethylammonium α-cyclodextrin phosphate, trimethylammonium β-cyclodextrin phosphate, trimethylammonium γ-cyclodextrin phosphate, trimethylammonium citrate, and trimethylammonium acetate.
11. The method of claim 7 , wherein the triethylammonium salt is selected from the group consisting of triethylammonium sulfate, triethylammonium sucrose octasulfate, triethylammonium α-Cyclodextrin sulfate, triethylammonium β-Cyclodextrin sulfate, triethylammonium γ-Cyclodextrin sulfate, triethylammonium phosphate, triethylammonium α-Cyclodextrin phosphate, triethylammonium β-Cyclodextrin phosphate, triethylammonium γ-Cyclodextrin phosphate, triethylammonium citrate, and triethylammonium acetate.
12. The method of claim 7 , wherein the protonating agent before reaction with the drug comprises triethylammonium sucrose octasulfate (TEA8SOS).
13. The method of claim 1 , wherein the nanoparticle drug carrier is a primary therapy in a chemotherapeutic regimen.
14. The method of claim 1 , wherein the nanoparticle drug carrier is a component in a multi-drug chemotherapeutic regimen.
15. The method of claim 14 , wherein the multi-drug chemotherapeutic regimen comprises at least two drugs selected from the group consisting of irinotecan (IRIN), oxaliplatin (OX), 5-fluorouracil (5-FU), and leucovorin (LV).
16. The method of claim 1 , wherein the cancer is pancreatic cancer, colorectal cancer, breast cancer, lung cancer, liver cancer, glioma, or melanoma.
17. The method of claim 1 , wherein the cancer is pancreatic ductal adenocarcinoma (PDAC).